Clinical Trial Update: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 study evaluating loncastuximab tesirine with rituximab versus immunochemotherapy in relapsed or refractory diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Loncastuximab tesirine (loncastuximab tesirine)
• Rituximab (rituximab)

Snippet

Sponsor: ADC Therapeutics S.A. | Conditions: Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING